Zobrazeno 1 - 10
of 127
pro vyhledávání: ''
Autor:
Suresh G. Nair Md, Jorge A. Rojas Zamalloa, Walid K. Chatila, Jedd D. Wolchok, Daniel G. Coit, Neal Rosen, Francisco Sanchez-Vega, Penina Krieger, Nikolaus Schultz, Klaus J. Busam, Margaret K. Callahan, Parisa Momtaz, Allison Betof Warner, Arshi Arora, Alexander N. Shoushtari, David B. Solit, Charlotte E. Ariyan, Havish S. Kantheti, Katherine S. Panageas, Christopher A. Barker, Mary S. Brady, Paul B. Chapman, Michael A. Postow
Publikováno v:
Clin Cancer Res
Purpose: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAPK pathway. Whether MAPK driver detection beyond BRAF V600 is clinically relevant in the checkpoint inhibitor era is unknown. Experimental Design: Pati
Autor:
Adel K. El-Naggar, Tatiana Karpinets, Danice T. Karagiannis, Renata Ferrarotto, Linton D. Sellen, Kristen B. Pytynia, Yoshitsugu Mitani, Andrew Futreal, Jianhua Zhang, Bin Liu
Publikováno v:
Clin Cancer Res
Purpose: Salivary gland carcinomas (SGCs) are pathologically classified into several widely diverse subtypes, of which adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), and salivary duct carcinoma (SDC) are the most commonly encountered
Autor:
Xun Wang, Kai Zhang, In Kyu Park, Jun Wang, Jian Cui, Bengang Hui, Samina Park, Haifeng Shen, Yuan Liu, Yuntao Nie, Hao Li, Chang Hyun Kang, Lixin Zhou, Yingshun Yang, Mingru Li, Jiabao Liu, Yaxiao Zhang, Young Tae Kim, Kezhong Chen, Yangming Zhang, Tian Guan, Yingtai Chen, Fan Yang, Yuqing Huang, Qingyi Qi, Guannan Kang
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(8)
Purpose: Nodule evaluation is challenging and critical to diagnose multiple pulmonary nodules (MPNs). We aimed to develop and validate a machine learning–based model to estimate the malignant probability of MPNs to guide decision-making. Experiment
Autor:
Claudio Zanna, Elisabeth Rouits, Rastislav Bahleda, Christophe Le Tourneau, Grégoire Vuagniaux, Carlos Gomez-Roca, Edith Borcoman, Eric Deutsch, Valentin Calugaru, A. Modesto, Jean Bourhis, Yungan Tao, Valerie Cristina, Jean-Pierre Delord, Kathrin Gollmer, Philippa Crompton, Sergio Szyldergemajn
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(24)
Purpose:Debio 1143 is an oral antagonist of inhibitor of apoptosis proteins, which enhances tumor response with concomitant chemoradiotherapy. Addition of Debio 1143 to cisplatin-based chemoradiotherapy in locally advanced squamous cell carcinomas of
Autor:
Robert A. Anders, Richard L. Blosser, Fabian M. Johnston, Elizabeth D. Thompson, Nicolas J. Llosa, Drew M. Pardoll, Ada J. Tam, Jessica Swailes, David J. McConkey, Jonathan B. Greer, John A. Ligon, Elizabeth A. Montgomery, Gady Cojocaru, Nicholas Siegel, Andriana Lebid, Carol D. Morris, Lingling Chen, Teniola Oke, Christian F. Meyer, Woonyoung Choi, Daniel S. Rhee, Brian H. Ladle, Adam S. Levin
Publikováno v:
Clin Cancer Res
Purpose: Clinical trials with immune checkpoint inhibition in sarcomas have demonstrated minimal response. Here, we interrogated the tumor microenvironment (TME) of two contrasting soft-tissue sarcomas (STS), rhabdomyosarcomas and undifferentiated pl
Autor:
Huiwen Jiang, Zhinan Yin, Lu Tang, Heng Mei, Mengyi Du, Chenggong Li, Jianghua Wu, Yu Hu, Min Xu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(7)
Purpose: This study aims to provide comprehensive insights into longitudinal immune landscape in acute myeloid leukemia (AML) development and treatment, which may contribute to predict prognosis and guide clinical decisions. Experimental Design: Peri
Autor:
Brian A. Van Tine, Jennifer A. Wargo, Richard F. Riedel, Emily Z. Keung, Sujana Movva, Jaime Rodrigues-Canales, Hussein Abdul-Hassan Tawbi, Edwin R. Parra, Christina L. Roland, Alexandre Reuben, Melissa Amber Burgess, Lara E. Davis, Denise K. Reinke, Alexander J. Lazar, James C. Hu, Steven Attia, Scott M. Schuetze, Dennis A. Priebat, Ruth Salazar, Vanessa Bolejack, Damon R. Reed, Wei Lien Wang, Scott H. Okuno
Publikováno v:
Clin Cancer Res
Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in undifferentiated pleomorphic sarcoma (UPS) and dedifferen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(20)
Purpose: The resistance to differentiation therapy and early death caused by fatal bleeding endangers the health of a significant proportion of patients with acute promyelocytic leukemia (APL). This study aims to investigate the molecular mechanisms
Autor:
Yi Bai, Ke Hu, Jie Pan, Li Huo, Haitao Zhao, Junping Shi, Lei Zhang, Yan Jiang, Junyu Long, Honglin Guo, Xinting Sang, Xu Yang, Xiaobo Yang, Xueshuai Wan, Kai Wang, Dongxu Wang, Mei Guan, Jianzhen Lin
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(15)
Purpose: Alterations in DNA damage repair (DDR) genes produce therapeutic biomarkers. However, the characteristics and significance of DDR alterations remain undefined in primary liver cancer (PLC). Experimental Design: Patients diagnosed with PLC we
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Autor:
Arantxa Uruñuela, Xuejing Aimee Wang, Alexander Drilon, Charles S. Fuchs, Sameera R. Wijayawardana, Ghassan K. Abou-Alfa, Brian A. Moser, Martin H. Voss, Johanna C. Bendell, T.K. Choueiri, Andrew X. Zhu, Volker Wacheck, Todd M. Bauer, James J. Harding
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(17)
Purpose: Inhibition of the VEGFR-2 blocks angiogenesis and attenuates tumor growth, but cancers may evade this effect through activation of the hepatocyte growth factor receptor MET. Here we report results of the phase Ib/II study of ramucirumab, a m